The partnership pairs miRecule’s RNA-design platform with peptide-based delivery to reach tissues current RNA therapies struggle to treat, starting with neuromuscular disease.
The joint investment expands device assembly for Lilly’s KwikPen in the Cincinnati region, adding at least 400 jobs as demand for diabetes and obesity injectables surges.
A $200 million trim to sales guidance and signs that an early demand surge had normalized wiped out roughly $12 billion in market value, as competition in the heart-disease market intensifies.
A Science study traced nine stages of metastasis and found a quiet, immune-evading cell state that, when disrupted, let the immune system fight the spreading cancer.
A US compounding group is marketing an under-the-tongue, unapproved version of the weight-loss drug to private UK clinics — a practice Novo Nordisk says risks patient safety.
Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.
The all-stock reverse merger, paired with a $278 million private placement, creates a Nasdaq-listed company built around CLD-423 for inflammatory bowel disease.
LTG-001, an oral Nav1.8 blocker, eased post-surgical pain and cut opioid rescue use in a 343-patient trial published in the New England Journal of Medicine.
The oral immunology drug ritlecitinib hit its co-primary endpoints in the TRANQUILLO studies, setting up filings for nonsegmental vitiligo, a condition with no approved oral therapy.
Vertex pays $28 million upfront and will fund all R&D for multispecific antibodies AbCellera discovers, pushing T-cell engagers beyond cancer into autoimmunity.
The Tokyo AI firm and Julien Orts’s NMR lab will combine machine learning with atomic-resolution spectroscopy to target intrinsically disordered proteins in cancer.
In the 106-patient HOPE-3 trial, boys and young men on deramiocel lost arm and elbow function markedly slower than those on placebo, ahead of an August FDA decision.